MOBILITY

10/2020- now

Neurologist, 1st Neurology Clinic , Eginition

Hospital, Greece

09.2017- now

Clinical and Research Fellow in the Movement Disorders Outpatient

Clinic, 1st Neurology Clinic , Eginition Hospital, University of Athens, Greece

03.2014- 04.2022

Clinical and Research Fellow in the Movement Disorders Outpatient Clinic, 2nd Neurology Clinic , Attikon Hospital, University of Athens, Greece

01.2010-01.2014

Neurology registrar, Eginition hospital, Athens

03.2014- now

Participation in Clinical Studies  : Since March 2014 investigator in the Parkinson’s Progression Markers Initiative study (PPMI) funded by the Michael J Fox Foundation. During 2018 participation in the DYSCOVER study funded by

Abbvie.

EDUCATION

01.2010-01.2014

Training in Neurology as a  registrar

Board certified on February 2014

11.2003 - 12.2007

PhD in Neurobiology

Medical School, National & Kapodistrian University of Athens, Greece, PhD Thesis title: “‘‘Chemotherapy induced neurotoxicity in the rodent cerebellum’’”

10.1995-04.2002

Medical Diploma (MD)

Medical School, National & Kapodistrian University of Athens, Greece (Grade 8.69/10)

REPRESENTATIVE PUBLICATIONS - SCHOLAR - ORCID

. 

• ‘Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. Koros C*, Stamelou M*, Simitsi A, Beratis I, Papadimitriou D, Papagiannakis N, Fragkiadaki S, Kontaxopoulou D, Papageorgiou SG, Stefanis L. ‘in Neurology. 2018 Mar 6;90(10):e864-e869. (* Equally contributed)
• ‘Genetics of Parkinson;s Disease: Genotype–Phenotype Correlations’ C. Koros, A. Simitsi, L. Stefanis in International Review of Neurobiology, 2017, 132:197-231.
• ‘123I-FP-CIT SPECT imaging in a p.A53T alpha-synuclein Parkinson’s disease cohort versus PD’. Koros, C., Simitsi, A., Prentakis, A., Beratis, I., Papadimitriou, D., Kontaxopoulou, D., Fragkiadaki, S., Papagiannakis, N., Seibyl, J., Marek, K., Papageorgiou, S.G., Geronicola Trapali, X., Stamelou, M , Stefanis, L.in Mov Disord. 2018 Oct 4. doi: 10.1002/mds.27451
• ‘Frontotemporal dementia spectrum: first genetic screen in a Greek cohort ’ Ramos EM., Koros C. , Dokuru DR., Van Berlo V., Kroupis C., Wojta K., Wang Q., Andronas N., Matsi S., Beratis I., Huang AY., Lee S., Bonakis A. , Florou-Hatziyiannidou C. , Fragkiadaki S., Kontaxopoulou D., Papastefanopoulou V.,Stamelou M., Miller BL., Stefanis L., Papatriantafyllou J.,. Papageorgiou SG.,Coppola G. In Neurobiol Aging, 2019 Mar;75:224.e1-224.e8.
• ‘’Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.’’ Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M. in Lancet Neurol. 2019 Jun 19. pii: S1474-4422(19)30140-1
• ‘’DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson;s disease: Longitudinal data from the PPMI study.’’ Koros C, Simitsi AM, Prentakis A, Papagiannakis N, Bougea A, Pachi I, Papadimitriou D, Beratis I, Papageorgiou SG, Stamelou M, Trapali XG, Stefanis L. in Parkinsonism Relat Disord. 2020 Jun 22;77:36-42. doi: 10.1016/j.parkreldis.2020.06.019.
• ‘’A Novel SNCA A30G Mutation Causes Familial Parkinson’s Disease.’ ’Liu H*, Koros C*, Strohäker T, Schulte C, Bozi M, Varvaresos S, Ibáñez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K, Maniati M, Papageorgiou SG, Hauser AK, Becker S, Zweckstetter M*, Stefanis L*, Gasser T.* in Mov Disord. 2021 Jul;36(7):1624-1633. (* Equally contributed)
• ‘’Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.’’ Koros C, Simitsi AM, Papadimitriou D, Bougea A, Prentakis A, Papagiannakis N, Pachi I, Bozi M, Antonelou R, Angelopoulou E, Beratis I, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. J Parkinsons Dis. 2020;10(2):481-487. doi: 10.3233/JPD-191860.
• ‘’Parkinsonism and dementia.’’ Koros C, Stefanis L, Scarmeas N. J Neurol Sci. 2022 Feb 15;433:120015. doi: 10.1016/j.jns.2021.120015.
• ‘’Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. ‘’Simitsi AM, Koros C, Stamelou M, Beratis I, Efthymiopoulou E, Papadimitriou D, Bougea A, Picillo M, Stanitsa E, Papagiannakis N, Antonelou R, Pachi I, Papageorgiou SG, Barone P, Stefanis L. Parkinsonism Relat Disord. 2022 May;98:72-74. doi: 10.1016/j.parkreldis.2022.04.001.